Pa. Risperdal Off-Label Trial Ends With Nonsuit For Janssen

PHILADELPHIA - (Mealey's) A Pennsylvania state court judge on June 14 granted Janssen Pharmaceutica Inc.'s motion for a nonsuit of the state government's third-party payer suit alleging that the drug company's off-label marketing of its atypical antipsychotic drug Risperdal resulted in...

West Virginia High Court Vacates $4.47M Judgment; FDA Warning Letters Not Matter Of Law

CHARLESTON, W.Va. -- (Mealey's) The West Virginia Supreme Court of Appeals on Nov. 18 reversed a $4,475,000 consumer law judgment against Johnson & Johnson concerning the marketing of Risperdal and Duragesic after agreeing with the defendant that the judge in a bench trial improperly relied on...

AstraZeneca Pays States $68.5M For Off-Label Marketing Of Seroquel Antipsychotic

TRENTON, N.J. - (Mealey's) AstraZeneca Pharmaceuticals L.P. and AstraZeneca L.P. on March 10 agreed to pay $68.5 million to 37 states and the District of Columbia to resolve allegations in a New Jersey state court lawsuit that it marketed its atypical antipsychotic drug Seroquel for off-label uses...

AstraZeneca Paying $68.5 Million In Seroquel Settlement

WASHINGTON, D.C. - (AP) AstraZeneca will pay $68.5 million as part of a multistate settlement over allegations that the drug developer promoted its blockbuster psychiatric drug Seroquel for insomnia, Alzheimer's and other unapproved uses. The New Jersey Attorney General's Office announced the...

South Carolina Judge: $327 Million Penalty Due For Marketing Of Risperdal

SPARTANBURG, S.C. - (Mealey's) A South Carolina state court judge on June 3 ordered the Ortho-McNeil-Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson to pay $327,073,700 for violating the state's Unfair Trade Practices Act by using deceptive practices to market the atypical antipsychotic...

Texas Risperdal Trial Ends When Janssen Settles For $158 Million, Company Says

AUSTIN, Texas -- Johnson & Johnson subsidiary Janssen LLP said Jan. 19 that it has agreed to pay $158 million to settle claims by Texas that it defrauded the Medicaid program through its off-label promotion of the atypical antipsychotic drug Risperdal ( State of Texas, ex rel. Allen Jones v. Janssen...

N.J. Risperdal Jury Finds Diabetes Warning Lacking, But Drug Didn't Cause Disease

NEW BRUNSWICK, N.J. - (Mealey's) A Risperdal personal injury trial ended Feb. 16 in a defense verdict for Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. after a New Jersey state court jury found that Janssen failed to warn about the risk of diabetes but that the atypical antipsychotic...

Arkansas Judge Orders J&J Unit To Pay $1.1 Billion Penalty For Risperdal Marketing

LITTLE ROCK, Ark. - (Mealey's) An Arkansas state court judge on April 11 assessed a $1.1 billion penalty against the Ortho-McNeil-Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson for thousands of violations of state trade practice and Medicaid fraud laws, sources told Mealey Publications...

Johnson & Johnson, 2 Units Plead Guilty, Pay $2.2 Billion In Criminal, Civil Penalties

WASHINGTON, D.C. — (Mealey’s) Two Johnson & Johnson subsidiaries have pleaded guilty, and the parent company and two subsidiaries will pay $2.2 billion in criminal fines, civil penalties and forfeitures in one criminal and several civil cases for off-label marketing of three drugs, for...

La. Supreme Court Reverses $330M Verdict For Risperdal Medicaid Law Violations

NEW ORLEANS — (Mealey’s) In a 4-3 vote, the Louisiana Supreme Court on Jan. 28 reversed a verdict of more than $330.6 million against Janssen Pharmaceutical Inc. and parent company Johnson & Johnson, finding that the state attorney general failed to prove that misrepresenting the safety...

Arkansas High Court Reverses $1.2B Risperdal Verdict For State Law Violations

LITTLE ROCK, Ark. — (Mealey’s) In a 4-3 decision, the Arkansas Supreme Court on March 20 reversed a $1.2 billion verdict against Janssen Pharmaceuticals for violating state law in its marketing of the antipsychotic drug Risperdal ( Ortho-McNeil-Janssen Pharmaceuticals, Inc., et al. v. State...